Tumor-targeted delivery of liposome-encapsulated doxorubicin by use of a peptide that selectively binds to irradiated tumors

Journal of Controlled Release

Volumn 150, Issue 1, 2011, Pages 117-124

  Lowery, Amanda ^a   Onishko, Halina ^a   Hallahan, Dennis E ^c   Han, Zhaozhong ^a,b  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c USA   (United States)

Author keywords

Doxorubicin; Liposomes; Lung cancer; Phage displayed peptide; Radiation guided drug delivery; Xenograft model

Indexed keywords

ALEXA FLUOR; ANTI-TUMOR EFFICACY; APOPTOSIS; BIODISTRIBUTIONS; CYTOTOXIC DRUGS; DOXORUBICIN; ENCAPSULATED DRUGS; HALF LIVES; IN-VIVO; LIPOSOMAL DOXORUBICIN; LUNG CANCER; MOLECULAR TARGETS; NEAR-INFRARED IMAGING; PEPTIDE LIBRARY; PHAGE-DISPLAYED PEPTIDE; PHARMACOKINETIC STUDIES; SELECTIVE BINDING; SINGLE-DOSE; TARGETED DELIVERY; TARGETED DRUG DELIVERY; TUMOR CELLS; TUMOR GROWTH; XENOGRAFT MODEL;

BIOCHEMISTRY; BIOLOGICAL MATERIALS; BIOLOGICAL ORGANS; BLOOD VESSELS; CELL DEATH; CELL PROLIFERATION; CYTOTOXICITY; DISEASES; DRUG DELIVERY; ENZYME INHIBITION; INFRARED DEVICES; LIPOSOMES; PEPTIDES; PHOSPHOLIPIDS; RADIOTHERAPY;

TUMORS;

DOXORUBICIN; HISTIDYLVALYLGLYCYLGLYCYLSERYLSERYLVALINE; LIPOSOME; PEPTIDE LIBRARY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RADIOTHERAPY; CELL DEATH; CELL PROLIFERATION; CYTOTOXICITY; DRUG HALF LIFE; DRUG RETENTION; HUMAN; HUMAN CELL; MOUSE; NEAR INFRARED SPECTROSCOPY; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; HUMANS; LIPOSOMES; LUNG; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; MICE, NUDE; PEPTIDES;

EID: 79951944883     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.11.006     Document Type: Article

References (42)

1. T.D. Wagner, G.Y. Yang, The role of chemotherapy and radiation in the treatment of locally advanced non-small cell lung cancer (NSCLC), Curr. Drug Targets 11 (2010) 67-73.
2. P.W. Pisters, S.R. Patel, V.G. Prieto, P.F. Thall, V.O. Lewis, B.W. Feig, K.K. Hunt, A.W. Yasko, P.P. Lin, M.G. Jacobson, M.A. Burgess, R.E. Pollock, G.K. Zagars, R.S. Benjamin, M.T. Ballo, Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas, J. Clin. Oncol. 22 (2004) 3375-3380.
3. J.T. Soper, S.A. Reisinger, R. Ashbury, E. Jones, D.L. Clarke-Pearson, Feasibility study of concurrent weekly cisplatin and whole abdominopelvic irradiation followed by doxorubicin/cisplatin chemotherapy for advanced stage endometrial carcinoma: a Gynecologic Oncology Group trial, Gynecol. Oncol. 95 (2004) 95-100.
4. A.B. Madhankumar, B. Slagle-Webb, X. Wang, Q.X. Yang, D.A. Antonetti, P.A. Miller, J.M. Sheehan, J.R. Connor, Efficacy of interleukin-13 receptor-targeted liposomal doxorubicin in the intracranial brain tumor model, Mol. Cancer Ther. 8 (2009) 648-654.
5. J.M. Tuscano, S.M. Martin, Y. Ma, W. Zamboni, R.T. O'Donnell, Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model, Clin. Cancer Res. 16 (2010) 2760-2768.
6. F. Danhier, O. Feron, V. Preat, To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery, J. Control Release 148 (2) (2010) 135-146.
7. R.S. DiPaola, J. Rinehart, J. Nemunaitis, S. Ebbinghaus, E. Rubin, T. Capanna, M. Ciardella, S. Doyle-Lindrud, S. Goodwin, M. Fontaine, N. Adams, A. Williams, M. Schwartz, G. Winchell, K. Wickersham, P. Deutsch, S.L. Yao, Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer, J. Clin. Oncol. 20 (2002) 1874-1879.
8. C.M. Hu, S. Kaushal, H.S. Tran Cao, S. Aryal, M. Sartor, S. Esener, M. Bouvet, L. Zhang, Half-antibody functionalized lipid-polymer hybrid nanoparticles for targeted drug delivery to carcinoembryonic antigen presenting pancreatic cancer cells, Mol. Pharm. 7 (3) (2010) 914-920.
9. I. Astsaturov, R.B. Cohen, P. Harari, EGFR-Targeting Monoclonal Antibodies in Head and Neck Cancer, Curr. Cancer Drug Targets 7 (2007) 650-665. (Pubitemid 350074968)
10. C.P. Leamon, J.A. Reddy, Folate-targeted chemotherapy, Adv. Drug Deliv. Rev. 56 (2004) 1127-1141. (Pubitemid 38496512)
11. P. Sini, L. Wyder, C. Schnell, T. O'Reilly, A. Littlewood, R. Brandt, N.E. Hynes, J. Wood, The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade, Clin. Cancer Res. 11 (2005) 4521-4532.
12. A. Nanda, B. St Croix, Tumor endothelial markers: new targets for cancer therapy, Curr. Opin. Oncol. 16 (2004) 44-49. (Pubitemid 38703471)
13. E. Ruoslahti, Targeting tumor vasculature with homing peptides from phage display, Semin. Cancer Biol. 10 (2000) 435-442.
14. T. Isayeva, S. Kumar, S. Ponnazhagan, Anti-angiogenic gene therapy for cancer (review), Int. J. Oncol. 25 (2004) 335-343.
15. R.S. Kerbel, Tumor angiogenesis: past, present and the near future, Carcinogenesis 21 (2000) 505-515.
16. T. Isayeva, D. Chanda, L. Kallman, I.-E.A. Eltoum, S. Ponnazhagan, Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP Model, 2007, pp. 5789-5797.
17. N. Madar-Balakirski, C. Tempel-Brami, V. Kalchenko, O. Brenner, D. Varon, A. Scherz, Y. Salomon, Permanent occlusion of feeding arteries and draining veins in solid mouse tumors by vascular targeted photodynamic therapy (VTP) with Tookad, PLoS One 5 (4) (2010) e10282.
18. G.P. Smith, Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface, Science 228 (1985) 1315-1317. (Pubitemid 15000355)
19. W. Arap, R. Pasqualini, E. Ruoslahti, Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model, Science 279 (1998) 377-380. (Pubitemid 28063372)
20. J.A. Joyce, P. Laakkonen, M. Bernasconi, G. Bergers, E. Ruoslahti, D. Hanahan, Stage-specific vascular markers revealed by phage display in amouse model of pancreatic islet tumorigenesis, Cancer Cell 4 (2003) 393-403. (Pubitemid 37491100)
21. R. Pasqualini, E. Ruoslahti, Organ targeting in vivo using phage display peptide libraries, Nature 380 (1996) 364-366. (Pubitemid 26097120)
22. E. Ruoslahti, Vascular zip codes in angiogenesis and metastasis, Biochem. Soc. Trans. 32 (2004) 397-402. (Pubitemid 38813523)
23. L. Geng, K. Osusky, S. Konjeti, A. Fu, D. Hallahan, Radiation-guided drug delivery to tumor blood vessels results in improved tumor growth delay, J. Control. Release 99 (2004) 369-381. (Pubitemid 39296906)
24. D. Hallahan, L. Geng, S. Qu, C. Scarfone, T. Giorgio, E. Donnelly, X. Gao, J. Clanton, Integrin-mediated targeting of drug delivery to irradiated tumor blood vessels, Cancer Cell 3 (2003) 63-74. (Pubitemid 37443891)
25. Z. Han, A. Fu, H. Wang, R. Diaz, L. Geng, H. Onishko, D.E. Hallahan, Noninvasive assessment of cancer response to therapy, Nat. Med. 14 (2008) 343-349.
26. D. Kirpotin, J.W. Park, K. Hong, S. Zalipsky, W.L. Li, P. Carter, C.C. Benz, D. Papahadjopoulos, Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro, Biochemistry 36 (1997) 66-75. (Pubitemid 27024679)
27. J.W. Park, K. Hong, D.B. Kirpotin, G. Colbern, R. Shalaby, J. Baselga, Y. Shao, U.B. Nielsen, J.D. Marks, D. Moore, D. Papahadjopoulos, C.C. Benz, Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery, Clin. Cancer Res. 8 (2002) 1172-1181.
28. J.W. Park, K. Hong, P. Carter, H. Asgari, L.Y. Guo, G.A. Keller, C. Wirth, R. Shalaby, C. Kotts, W.I. Wood, et al., Development of anti-p185HER2 immunoliposomes for cancer therapy, Proc. Natl Acad. Sci. USA 92 (1995) 1327-1331.
29. G. Haran, R. Cohen, L.K. Bar, Y. Barenholz, Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases, Biochim. Biophys. Acta 1151 (1993) 201-215.
30. M.J. Parr, D. Masin, P.R. Cullis, M.B. Bally, Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol), J. Pharmacol. Exp. Ther. 280 (1997) 1319-1327.
31. G. Thurston, J.W. McLean, M. Rizen, P. Baluk, A. Haskell, T.J. Murphy, D. Hanahan, D.M. McDonald, Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice, J. Clin. Investig. 101 (1998) 1401-1413.
32. S.V. Kozin, F. Winkler, I. Garkavtsev, D.J. Hicklin, R.K. Jain, Y. Boucher, Human tumor xenografts recurring after radiotherapy are more sensitive to anti-vascular endothelial growth factor receptor-2 treatment than treatment-naive tumors, Cancer Res. 67 (2007) 5076-5082. (Pubitemid 46997241)
33. L. Agemy, K.N. Sugahara, V.R. Kotamraju, K. Gujraty, O.M. Girard, Y. Kono, R.F. Mattrey, J.H. Park, M.J. Sailor, A.I. Jimenez, C. Cativiela, D. Zanuy, F.J. Sayago, C. Aleman, R. Nussinov, E. Ruoslahti, Nanoparticle-induced vascular blockade in human prostate cancer, Blood 116 (15) (2010) 2847-2856.
34. J. Hamzah, J.G. Altin, T. Herringson, C.R. Parish, G.J. Hammerling, H. O'Donoghue, R. Ganss, Targeted liposomal delivery of TLR9 ligands activates spontaneous antitumor immunity in an autochthonous cancer model, J. Immunol. 183 (2009) 1091-1098.
35. D.E. Hallahan, M.J. Staba-Hogan, S. Virudachalam, A. Kolchinsky, X-ray-induced P-selectin localization to the lumen of tumor blood vessels, Cancer Res. 58 (1998) 5216-5220. (Pubitemid 28521185)
36. S. Ram, D.J. Buchsbaum, Radioiodination of monoclonal antibodies D612 and 17-1A with 3-iodophenylisothiocyanate and their biodistribution in tumor-bearing nude mice, Cancer 73 (1994) 808-815. (Pubitemid 24046635)
37. D.E. Hallahan, L. Geng, A.J. Cmelak, A.B. Chakravarthy, W. Martin, C. Scarfone, A. Gonzalez, Targeting drug delivery to radiation-induced neoantigens in tumor microvasculature, J. Control. Release 74 (2001) 183-191. (Pubitemid 32727620)
38. D.E. Hallahan, H.J. Mauceri, L.P. Seung, E.J. Dunphy, J.D. Wayne, N.N. Hanna, A. Toledano, S. Hellman, D.W. Kufe, R.R. Weichselbaum, Spatial and temporal control of gene therapy using ionizing radiation, Nat. Med. 1 (1995) 786-791.
39. N. Kasahara, A.M. Dozy, Y.W. Kan, Tissue-specific targeting of retroviral vectors through ligand-receptor interactions, Science 266 (1994) 1373-1376.
40. H. Wang, H. Yan, A. Fu, M. Han, D. Hallahan, Z. Han, TIP-1 translocation onto the cell plasma membrane is a molecular biomarker of tumor response to ionizing radiation, PLoS One 5 (8) (2010) e12051.
41. I.E. Palama, S. Leporatti, E. de Luca, N. Di Renzo, M. Maffia, C. Gambacorti-Passerini, R. Rinaldi, G. Gigli, R. Cingolani, A.M. Coluccia, Imatinib-loaded polyelectrolyte microcapsules for sustained targeting of BCR-ABL+ leukemia stem cells, Nanomedicine (Lond) 5 (3) (2010) 419-431.
42. R.J. Passarella, D.E. Spratt, A.E. van der Ende, J.G. Phillips, H. Wu, V. Sathiyakumar, L. Zhou, D.E. Hallahan, E. Harth, R. Diaz, Targeted nanoparticles that deliver a sustained, specific release of Paclitaxel to irradiated tumors, Cancer Res. 70 (11) (2010) 4550-4559.